Laffi Alice, Gervaso Lorenzo, D'Ecclesiis Oriana, Gandini Sara, Riva Agostino, Passerini Rita, Spada Francesca, Pellicori Stefania, Rubino Manila, Cella Chiara Alessandra, Ravenda Paola Simona, Zampino Maria Giulia, Fazio Nicola
Division of Gastrointestinal and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Biomedicines. 2023 Jan 25;11(2):336. doi: 10.3390/biomedicines11020336.
The coronavirus disease-19 (COVID-19) pandemic dramatically impacted oncological patients' care. Since the introduction of vaccines and the demonstration of their benefit on frail patients, COVID-19 vaccinations were indicated to also be beneficial to oncological population. However, data about the impact of anticancer-treatments and the timing between vaccinations and systemic therapy delivery were not available. We aimed to evaluate potential factors influencing the outcome of the COVID-19 vaccination in cancer patients. We prospectively collected data of patients undergoing the COVID-19 vaccination with gastro-entero-pancreatic and neuroendocrine neoplasms, treated at our institute, between 03/2021 and 12/2021. We enrolled 46 patients, 63.1% males; at the time of data collection, 86.9% had received two-doses of Pfizer-BioNTech and the rest had received the Moderna vaccine. All patients obtained a subsequent immune-response. Chemotherapy seems to determinate a significantly lower antibody response after vaccination compared to the other anti-cancer agents ( = 0.004). No significant effect on immune-response was reported for both vaccinations performed ≤7 vs. >7 days from the last systemic treatment ( = 0.77) and lymphocytes count ( = 0.11). The findings suggest that the optimal timing for COVID-19 vaccination and lymphocytes count are not the issue, but rather that the quality of the subset of lymphocytes before the vaccination determine the efficacy level of immune-response in this population.
新型冠状病毒肺炎（COVID-19）大流行对肿瘤患者的护理产生了巨大影响。自从疫苗问世并证明其对体弱患者有益以来，COVID-19疫苗接种也被认为对肿瘤患者有益。然而，关于抗癌治疗的影响以及疫苗接种与全身治疗给药之间的时间间隔的数据尚不可用。我们旨在评估影响癌症患者COVID-19疫苗接种结果的潜在因素。我们前瞻性地收集了2021年3月至2021年12月期间在我们研究所接受COVID-19疫苗接种的胃肠胰和神经内分泌肿瘤患者的数据。我们纳入了46例患者，男性占63.1%；在数据收集时，86.9%的患者接种了两剂辉瑞-BioNTech疫苗，其余患者接种了Moderna疫苗。所有患者均获得了后续的免疫反应。与其他抗癌药物相比，化疗似乎在疫苗接种后产生的抗体反应明显较低（P = 0.004）。对于在最后一次全身治疗后≤7天与>7天进行的疫苗接种（P = 0.77）以及淋巴细胞计数（P = 0.11），均未报告对免疫反应有显著影响。研究结果表明，COVID-19疫苗接种的最佳时间和淋巴细胞计数不是问题，而是疫苗接种前淋巴细胞亚群的质量决定了该人群免疫反应的效力水平。
